Gent, BELGIUM – July 15, 2018 – Oxyrane, a private biotechnology company developing novel enzyme replacement therapies, today announced the award of a grant from the Michael J. Fox Foundation. The grant is issued under the Therapeutic Pipeline Program of the Michael J. Fox Foundation, aimed to fund projects with potential for fundamentally altering disease course and/or significantly improving treatment of symptoms above and beyond current standard of care.
Oxyrane project entitled “Innovative Glucocerebrosidase enzyme therapy as a disease-modifying systemic treatment for Parkinson’s disease” was funded to support the advancement of the Parkinson’s disease program at Oxyrane.
Parkinson’s disease is one of the most prevalent and debilitating neurodegenerative disorders, with a high need for disease-modifying treatments. Approximately 10% of patients with Parkinson’s disease have mutations in the GBA1 gene, which constitute the most common genetic risk factor for developing Parkinson’s disease. Enhancing Glucocerebrosidase levels in the brain is a highly promising strategy to limit the accumulation of a-synuclein, and has the potential to address both motor and non-motor symptoms in Parkinson’s disease patients.
About Michael J. Fox Foundation
The Michael J. Fox Foundation for Parkinson’s Research works tirelessly to accelerate promising research toward breakthroughs for Parkinson's patients. It provides support to accelerate the therapeutic development in Parkinson's disease through a number of initiatives. The Therapeutic Pipeline Program is part of their Edmond J. Safra Core Programs for PD Research.
Oxyrane is focused on development of novel enzyme therapies for the treatment of severe lysosomal storage disorders, including Gaucher, Pompe and Parkinson’s disease.
Oxyrane has developed a proprietary platform for the production of enzymes with enhanced phosphorylation of the sugar structures on the surface. This system generates enzymes with very high cellular uptake and subcellular targeting, potentially allowing for a superior efficacy at lower doses of enzyme therapies.
Oxyrane is a private company with operations in Manchester, UK and Gent, Belgium. It is backed by top-tier venture capital investors, New Science Ventures (New York) and Forbion Capital Partners (the Netherlands), and supported by a board with renowned leaders in the development of innovative therapies - Philip Astley-Sparke, Leonard Post, Charles Richard, Hans Preusting, Sander Slootweg and Somu Subramaniam.
For further information, please contact:
Wouter Vervecken, PhD
Chief Executive Officer, Oxyrane